{{위키데이터 속성 추적}}
{{Infobox drug
| IUPAC_name = [(2''S'',5''R'')-2-Carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
| image = Avibactam structure 2.svg
| width = 200
| image2 = Avibactam ball-and-stick model.png
| alt =
| caption =

<!-- Clinical data -->
| tradename = 아비카즈(Avycaz, 세프타지딤 복합약), 엠블라베오(Emblaveo, 아조트레오남 복합약)
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category=
| routes_of_administration = [[정맥 주사]]

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status =

<!-- Pharmacokinetic data -->
| bioavailability = 100% (IV)
| protein_bound = 5.7~8.2%<ref>{{웹 인용|title=Full Prescribing Information: Avycaz (ceftazidime-avibactam) for Injection, for intravenous use|url=http://pi.actavis.com/data_stream.asp?product_group=1957&p=pi&language=E|archive-url=https://web.archive.org/web/20150602094121/http://pi.actavis.com/data_stream.asp?product_group=1957&p=pi&language=E|url-status=dead|archive-date=2 June 2015|publisher=©2015 Actavis. All rights reserved.|access-date=1 June 2015}}</ref>
| metabolism = 미미함
| onset = 용량에 따라 증가
| elimination_half-life =
| excretion = [[콩팥]] (97%)

<!-- Identifiers -->
| CAS_number = 1192500-31-4
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7352665165
| ATCvet =
| ATC_prefix = None
| ATC_suffix =
| PubChem = 9835049
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 85984
| ChemSpiderID = 8010770
| KEGG = D10340
| DrugBank =

<!-- Chemical data -->
| chemical_formula =
| C=7 | H=11 | N=3 | O=6 | S=1
| smiles= [C@]12C[N@]([C@@H](CC1)C(N)=O)C(=O)N2OS(O)(=O)=O
| ChEMBL = 1689063
| StdInChI = 1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
| StdInChIKey = NDCUAPJVLWFHHB-UHNVWZDZSA-N
}}

'''아비박탐'''(Avibactam)은 비(非)-[[베타-락탐]]인 [[베타-락타메이스 억제제]]로,<ref>{{저널 인용| vauthors = Wang DY, Abboud MI, Markoulides MS, Brem J, Schofield CJ | title = The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam | journal = Future Medicinal Chemistry | volume = 8 | issue = 10 | pages = 1063–1084 | date = June 2016 | pmid = 27327972 | doi = 10.4155/fmc-2016-0078 | doi-access = free }}</ref> [[액타비스]](現 [[테바 파마수티컬스|테바]])가 [[아스트라제네카]]와 공동으로 개발했다. [[세프타지딤]]과의 [[복합약]]인 [[세프타지딤/아비박탐]](상품명 아비카즈, Abycaz)이 2015년 2월 25일, 다제내성 [[그람 음성균]]으로 인한 복합 [[요로감염증]](cUTI)과 복합 [[복강내감염]](cIAI) 치료에 대해 [[미국 식품의약국|FDA]] 승인을 받았다.<ref>{{저널 인용| vauthors = Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA | display-authors = 6 | title = Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination | journal = Drugs | volume = 73 | issue = 2 | pages = 159–177 | date = February 2013 | pmid = 23371303 | doi = 10.1007/s40265-013-0013-7 | s2cid = 32700350 | url = https://zenodo.org/record/1230313 }}</ref><ref>{{웹 인용|title=Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product|url=http://www.actavis.com/news/news/thomson-reuters/actavis-announces-fda-acceptance-of-the-nda-filing|website=Actavis—a global, integrated specialty pharmaceutical company—Actavis|publisher=Actavis plc|access-date=1 June 2015|archive-url=https://web.archive.org/web/20150527032942/http://www.actavis.com/news/news/thomson-reuters/actavis-announces-fda-acceptance-of-the-nda-filing|archive-date=27 May 2015|url-status=dead}}</ref><ref>{{저널 인용| vauthors = Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL | display-authors = 6 | title = Kinetics of avibactam inhibition against Class A, C, and D β-lactamases | journal = The Journal of Biological Chemistry | volume = 288 | issue = 39 | pages = 27960–27971 | date = September 2013 | pmid = 23913691 | pmc = 3784710 | doi = 10.1074/jbc.M113.485979 | doi-access = free }}</ref> 한편 [[아즈트레오남]]과의 복합약인 [[아즈트레오남/아비박탐]](상품명 엠블라베오, Emblaveo)은 [[애브비]]와 [[화이자]]가 호기성 그람 음성균 감염 치료를 위해 개발했다.<ref name="Emblaveo PI">{{웹 인용| title=Emblaveo Product information | website=Union Register of medicinal products | date=22 April 2024 | url=https://ec.europa.eu/health/documents/community-register/html/h1808.htm | access-date=22 April 2024}}</ref><ref>{{웹 인용|title=Pipeline |url=https://www.abbvie.com/science/pipeline.html |website=AbbVie |access-date=25 November 2023 |archive-date=25 November 2023 |archive-url=https://web.archive.org/web/20231125080555/https://www.abbvie.com/science/pipeline.html |url-status=live }}</ref><ref>{{저널 인용|last1=Sader |first1=Helio S |last2=Castanheira |first2=Mariana |last3=Kimbrough |first3=John H |last4=Kantro |first4=Valerie |last5=Mendes |first5=Rodrigo E |title=Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21) |journal=JAC-Antimicrobial Resistance |date=22 March 2023 |volume=5 |issue=2 |pages=dlad032 |doi=10.1093/jacamr/dlad032 |pmid=36968952 |pmc=10032302 |issn=2632-1823}}</ref><ref>{{저널 인용|last1=Livermore |first1=David M. |last2=Mushtaq |first2=Shazad |last3=Vickers |first3=Anna |last4=Woodford |first4=Neil |title=Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli |journal=International Journal of Antimicrobial Agents |date=May 2023 |volume=61 |issue=5 |pages=106776 |doi=10.1016/j.ijantimicag.2023.106776|pmid=36893810 |s2cid=257428399 |doi-access=free }}</ref> 2024년 4월 EU에서 다제내성 그람 음성균으로 인한 cUTI와 cIAI, [[원내감염]]으로 인한 [[폐렴]] 치료에 대한 사용을 최종 승인했다.<ref name="Emblaveo EPAR">{{웹 인용| title=Emblaveo EPAR | website=European Medicines Agency | date=21 March 2024 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/emblaveo | access-date=23 March 2024 | archive-date=23 March 2024 | archive-url=https://web.archive.org/web/20240323162104/https://www.ema.europa.eu/en/medicines/human/EPAR/emblaveo | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref>{{웹 인용|url=https://www.yna.co.kr/view/AKR20240422153300098|제목=EU, 화이자의 다제내성 항생제 '엠블라베오' 승인|성=정빛나|웹사이트=연합뉴스|날짜=2024-04-22|언어=ko|확인날짜=2024-05-12}}</ref>

그람 음성균, 특히 원내감염에서 [[세팔로스포린]] 내성 비율이 증가하는 것은 세팔로스포린 계열 항생제를 비활성화시킬 수 있는 [[베타-락타메이스]]를 만드는 균주가 점차 증가하고 있기 때문이다. 베타-락타메이스 억제제를 병용하여 이러한 효소를 억제해  세팔로스포린 활성을 회복할 수 있으나, 아비박탐보다 먼저 사용이 승인되었던 베타-락타메이스 억제제인 [[타조박탐]]과 [[클라불란산]]은 여러 주요 베타-락타메이스를 억제하지 못했다. 그 예시로는 [[폐렴간균]](''Klebsiella pneumoniae'')의 카바페네메이스(KPCs), [[뉴델리 메탈로-베타락타메이스]](NDM-1), AmpC형 베타-락타메이스 등이 있다. 반면 아비박탐은 클래스 A (KPCs, CTX-M, TEM, SHV), 클래스 C (AmpC), 일부 클래스 D 세린 베타-락타메이스 (OXA-23, OXA-48)를 억제한다. 그러나 아비박탐은  VIM-2, VIM-4, SPM-1, BcII, NDM-1, Fez-1 등의 클래스 B 메탈로 베타-락타메이스는 잘 억제하지 못한다고 보고되었다.<ref>{{저널 인용| vauthors = Abboud MI, Damblon C, Brem J, Smargiasso N, Mercuri P, Gilbert B, Rydzik AM, Claridge TD, Schofield CJ, Frère JM | display-authors = 6 | title = Interaction of Avibactam with Class B Metallo-β-Lactamases | journal = Antimicrobial Agents and Chemotherapy | volume = 60 | issue = 10 | pages = 5655–5662 | date = October 2016 | pmid = 27401561 | pmc = 5038302 | doi = 10.1128/AAC.00897-16 }}</ref>

== 각주 ==
{{각주}}

== 외부 링크 ==
* {{콘퍼런스 인용| vauthors = Edeki T, Armstrong J, Li J | title = Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers. | id = Poster A-1019 | conference = 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) | date = September 2013 | volume = 10 | page = 13 |url= http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2013/A/2013_A-1019.htm |url-status=dead |archive-url= https://web.archive.org/web/20160303213124/http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2013/A/2013_A-1019.htm |archive-date=2016-03-03 }}

[[분류:베타-락타메이스 억제제]]
[[분류:질소 헤테로고리 화합물]]
[[분류:황산 에스터]]